Hsien-Yen Chang

Hsien-Yen Chang

Auto-generated profile, based on publicly available information

Hsien-Yen Chang

Johns Hopkins Bloomberg School of Public Health

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
SSSonal Singh
Sonal Singh
HCHsien-Yen Chang
Hsien-Yen Chang
TRThomas M. Richards
Thomas M. Richards
JWJonathan P. Weiner
Jonathan P. Weiner
JCJeanne M. Clark
Jeanne M. Clark
JSJodi B. Segal
Jodi B. Segal
The glucagonlike peptide 1 (GLP-1)–based therapies include a GLP-1 mimetic, exenatide, and a dipeptidyl peptidase 4 inhibitor, sitagliptin phosphate. These therapies are used in patients with type 2 diabetes mellitus to lower blood glucose levels. Exenatide is a subcutaneous injectable GLP-1 agonist that enhances glucose-mediated insulin secretion. Sitagliptin is an oral dipeptidyl peptidase 4 inhibitor that prevents the proteolysis of endogenous GLP-1.1

1 October 2013 in Medical Care
Verified
Journal Article
Closed access
MDMatthew Daubresse
Matthew Daubresse
HCHsien-Yen Chang
Hsien-Yen Chang
YYYuping Yu
Yuping Yu
SVShilpa Viswanathan
Shilpa Viswanathan
NSNilay D. Shah
Nilay D. Shah
GAG. Caleb Alexander
G. Caleb Alexander
Background: Escalating rates of prescription opioid use and abuse have occurred in the context of efforts to improve the treatment of nonmalignant pain. Objective: The aim of the study was to characterize the diagnosis and management of nonmalignant pain in ambulatory, office-based settings in the United States between 2000 and 2010. Design, Setting, and Participants: Serial cross-sectional and multivariate regression analyses of the National Ambulatory Medical Care Survey (NAMCS), a nationally representative audit of office-based physician visits, were conducted. Measures: (1) Annual visit volume among adults with primary pain symptom or diagnosis; (2) receipt of any pain treatment; and (3) receipt of prescription opioid or nonopioid pharmacologic therapy in visits for new musculoskeletal pain. Results: Primary symptoms or diagnoses of pain consistently represented one-fifth of visits, varying little from 2000 to 2010. Among all pain visits, opioid prescribing nearly doubled from 11.3% to 19.6%, whereas nonopioid analgesic prescribing remained unchanged (26%–29% of visits). One-half of new musculoskeletal pain visits resulted in pharmacologic treatment, although the prescribing of nonopioid pharmacotherapies decreased from 38% of visits (2000) to 29% of visits (2010). After adjusting for potentially confounding covariates, few patient, physician, or practice characteristics were associated with a prescription opioid rather than a nonopioid analgesic for new musculoskeletal pain, and increases in opioid prescribing generally occurred nonselectively over time. Conclusions: Increased opioid prescribing has not been accompanied by similar increases in nonopioid analgesics or the proportion of ambulatory pain patients receiving pharmacologic treatment. Clinical alternatives to prescription opioids may be underutilized as a means of treating ambulatory nonmalignant pain.

1 July 2017 in Medical Care
Verified
Journal Article
Open access
JSJodi B. Segal
Jodi B. Segal
HCHsien-Yen Chang
Hsien-Yen Chang
YDYu Du
Yu Du
JWJeremy D. Walston
Jeremy D. Walston
MCMichelle C. Carlson
Michelle C. Carlson
RVRavi Varadhan
Ravi Varadhan
Background: Fried and colleagues described a frailty phenotype measured in the Cardiovascular Health Study (CHS). This phenotype is manifest when ≥3 of the following are present: low grip strength, low energy, slowed waking speed, low physical activity, or unintentional weight loss. We sought to approximate frailty phenotype using only administrative claims data to enable frailty to be assessed without physical performance measures.Study Design: We used the CHS cohort data linked to participants Medicare claims. The reference standard was the frailty phenotype measured at visits 5 and 9. With penalized logistic regression, we developed a parsimonious index for predicting the frailty phenotype using a linear combination of diagnoses, operationalized with claims data. We assessed the predictive validity of frailty index by examining how well it predicted common aging-related outcomes including hospitalization, disability, and death.Results: There were 4454 CHS participants from 4 clinical sites. In total, 84% were white, 58% were women and their mean age was 72 years at enrollment. Approximately 11% of the cohort was frail. The model had an area under the receiver operating curve of 0.75 to concurrently predict a frailty phenotype. This Claims-based Frailty Indicator significantly predicted death (odds ratio, 1.84), time to death (hazards ratio, 1.71), number of hospital admissions (incidence rate ratio, 1.74), and nursing home admission (odds ratio, 1.47) in models adjusted for age and sex.Conclusions: Claims data alone can be used to classify individuals as frail and nonfrail. The Claims-based Frailty Indicator might be used in research with large datasets for confounding adjustment or risk prediction. The indicator might also be used for emergency preparedness for identification of regions enriched with frail individuals.

1 October 2015 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
LRLainie Rutkow
Lainie Rutkow
HCHsien-Yen Chang
Hsien-Yen Chang
MDMatthew Daubresse
Matthew Daubresse
DWDaniel W. Webster
Daniel W. Webster
ESElizabeth A. Stuart
Elizabeth A. Stuart
GAG. Caleb Alexander
G. Caleb Alexander
Prescription opioids provide necessary analgesia to millions of Americans, yet the country faces soaring rates of opioid diversion, addiction, and overdose deaths.1-3 In the mid-2000s, Florida emerged as the epicenter of this epidemic. From 2003 to 2009, prescription drug overdose deaths in Florida increased more than 80%.4 In 2010, among the 100 US physicians purchasing the greatest amounts of oxycodone, 90 were in Florida.5 As a direct response, in 2010, Florida’s legislature addressed pill mills, or rogue pain management clinics where prescription drugs are inappropriately prescribed and dispensed.6 Florida’s pill mill law required these clinics to register with the state and have a physician-owner, created inspection requirements, and established prescribing and dispensing requirements and prohibitions for physicians at these clinics. The law’s implementation began in 2010, with additional elements becoming effective in July 2011 that prohibited prescriber dispensing of certain drugs.7 In September 2011, Florida’s Prescription Drug Monitoring Program (PDMP) became operational.8 Florida’s PDMP uses an electronic database to collect information about prescription drugs dispensed within the state. Florida-based prescribers and dispensers may voluntarily access the PDMP’s information to review individuals’ history to identify and address problematic practices such as physician shopping.9 Within the first 3 months of operation, more than 8000 prescribers registered, and the PDMP received almost 340 000 queries. After 1 year, in September 2012, the PDMP had received more than 2.3 million queries from more than 18 000 registered prescribers.10

29 January 2014 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
WBWendy L Bennett
Wendy L Bennett
HCHsien-Yen Chang
Hsien-Yen Chang
DLDavid M. Levine
David M. Levine
LWLin Wang
Lin Wang
DNDonna Neale
Donna Neale
JCJeanne M. Clark
Jeanne M. Clark

1 November 2012
Verified
Journal Article
Closed access
HCHsien-Yen Chang
Hsien-Yen Chang
JWJonathan P Weiner
Jonathan P Weiner
TRThomas M Richards
Thomas M Richards
SBSara N Bleich
Sara N Bleich
JSJodi B Segal
Jodi B Segal